IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection by Chen, J-Y et al.
ORIGINAL ARTICLE
IL28B genetic variations are associated with high
sustained virological response (SVR) of interferon-a plus
ribavirin therapy in Taiwanese chronic HCV infection
J-Y Chen
1, C-Y Lin
2, C-M Wang
3, Y-T Lin
1, S-N Kuo
1, C-F Shiu
4, S-W Chang
4,JW u
5 and I-S Sheen
2
1Department of Medicine, Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital, Chang Gung
University College of Medicine, Taiwan, Republic of China;
2Department of Medicine, Division of Hepatology and Gastroenterology,
Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taiwan, Republic of China;
3Department of
Rehabilitation, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taiwan, Republic of China;
4Division of
Biostatistics, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, Republic of China and
5Department of Veterinary and
Biomedical Sciences, University of Minnesota, St Paul, MN, USA
Chronic hepatitis C virus (HCV) infection patients exhibit different sustained virological responses (SVRs) following the
treatment with pegylated interferon-a (IFN-a) and ribavirin. Genome-wide association studies consistently linked SVR of IFN-a-
based therapy to the IL28B single-nucleotide polymorphisms (SNPs) on chromosome 19q.13 in various populations. This study
was undertaken to investigate the association of IL28B SNPs with SVR in a cohort of Taiwanese chronic HCV patients. Ten
SNPs of IL28B were genotyped in 728 chronic HCV patients and 960 healthy controls. Genotype distributions, allele
frequencies and haplotypes were tested for SVR and susceptibility in Taiwanese chronic HCV patients. Non-genotype 1
infection (adjusted P¼3.3 10
 12, odds ratio (OR) 0.179; 95% confidence interval (CI): 0.110–0.290) and low HCV viral load
(o400000IUml
–1) (adjusted P¼3.5 10
 9, OR 0.299; 95% CI: 0.200–0.446) were two major factors identified for high SVR.
Notably, eight IL28B SNPs including previously described disease-associated SNPs (Trend test P¼0.005) were significantly
associated with SVR. Our data indicate that IL28B polymorphisms are the essential contributing factors for high SVR in
Taiwanese chronic HCV patients. Combination of virus genotyping and host genetic data may be used to select the optimal
treatment regimes in IFN-based therapy.
Genes and Immunity (2011) 12, 300–309; doi:10.1038/gene.2011.1; published online 24 February 2011
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Introduction
Hepatitis C virus (HCV) infection, the leading cause of
chronic liver disease, is emerging as a global concern of
public health inflicting up to 3% human populations.
1 HCV
infection usually appears as an asymptomatic disease,
which accompanies the development of chronic persistent
viremia in majority individuals despite substantial virus
and host cellular immune responses.
2–4 HCV chronic
infection associates with an intra-hepatic inflammatory
infiltration, which is frequently followed by progressive
fibrosis that leads to liver cirrhosis and ultimately to the
development of hepatocellular carcinoma.
5–7
HCV infection induces the production of interferons
(IFNs), especially IFN a (IFN-a), in part through viral
nucleic acid interactions with distinct pathogen-asso-
ciated molecular pattern recognition receptors, such as
Toll-like receptors on cell surface and/or intracellular
sensors, such as retinoic acid-inducible gene I like
helicases in the infected host cells.
8–11 The IFN signaling
pathways activate IFN-stimulated genes (ISGs), which
play critical roles in the host innate defense against HCV
infection through repressing viral replication and
enhancing cellular immune responses.
9,11,12 Pegylated
IFN-a plus ribavirin therapy became the standard
therapy for HCV viral infection recently. However, the
therapy failed to cure all patients who underwent
the treatment. In addition, patients may encounter
specific adverse effects that require therapy withdra-
wal.
13 The interplay of the virus, environmental factors
and the host immunity is implicated as the key process
for the natural heterogeneity of viral clearance and liver
injury.
14–19 It remains a critical issue with regard to the
viral persistence and the response to anti-viral therapy in
individual patient.
Interferon l (IFN-l) is classified as the type 3 IFN that
includes three subtypes (IFN-l1, 2 and 3). IFN-ls
have pleiotropic cellular functions. The ligand receptor
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by IFN-a and b.
20,21 IFN-ls are produced and expressed
in antigen-presenting cells. IFN-ls have lower antiviral
activities than IFN-a. However, IFN-ls have critical roles
in fighting against viral infection.
22–24 Recently, four
genome-wide association studies concurrently provided
the overwhelming evidence that single-nucleotide poly-
morphisms (SNPs) of IFN-l3 (also known as IL28B) on
chromosome 19q13 contribute to IFN treatment response
and spontaneous HCV clearance in HCV infection.
25–29
Meanwhile, IL28B genetic variations influence the IL28B
mRNA expressions, which may have a role in the
regulation of intra-hepatic ISG expression.
26,27 IL28B
SNPs seem to impact the treatment response to pegy-
lated IFN-a/ribavirin for chronic HCV infection among
several ethnic populations.
25–29 In this study, we inves-
tigated whether the IL28B polymorphisms are associated
with susceptibility to HCVinfection and with response to
the therapy of IFN and ribavirin in Taiwanese chronic
HCV infection patients.
Results
Clinical characteristics of chronic HCV infection patients
This study recruited 728 Taiwanese patients with chronic
HCV infection including 444 men and 284 women who
received IFN-a plus ribavirin therapy. The mean ages on
therapy were 51.2±10.4 (ranged 19.2–76.5) years old.
Among them, 126 patients (112 patients were treated for
a period of 24 weeks and 14 patients for 48 weeks)
received treatment of INTRON 5MU three times a week
in combination of 1200mg ribavirin daily. The remaining
602 patients received ribavirin (1200mg) daily and
pegylated IFN-a every week (499 patients were treated
for a period of 24 weeks and 103 patients for 48 weeks).
Of the total 728 chronic HCV patients, 559 (76.8%)
revealed sustained virological response (SVR) to IFN
(INTRON or pegylated IFN-a) plus ribavirin therapy. In
addition, 424 (58.2%) were identified as HCV genotype 1
viral infection and 318 (43.7%) were detected with viral
load over 400000IUml
–1 (Table 1). The liver biopsies
showed that 246 (33.8%) were in cirrhosis stage, 114
(15.7%) in severe fibrosis stage and 368 (50.5%) in mild
fibrosis stage.
Clinical characteristics affect SVR during the treatment
of chronic HCV infection
We examined the possible factors that may contribute to
the SVR of chronic HCV infection. As shown in Table 2,
age at therapy and gender were important host factors
that affected the SVR. Patients with younger age at
therapy were more likely to have higher SVR rate in
chronic HCV infection (adjusted P¼0.0004, odds ratio
(OR) 0.962; 95% confidence interval (CI): 0.942–0.983).
The SVR rate tended to be higher (81.3%) in men than in
women (69.8%) (adjusted P¼0.0093, OR 1.705; 95% CI:
1.140–2.549). Non-cirrhosis (mild and severe fibrosis) is
another critical factor that demonstrated high SVR in
comparison with cirrhosis (adjusted P¼4.1 10
 6,O R
0.379; 95% CI: 0.251–0.573). Body mass index below
27kgm
–2 showed modest effect on the higher SVR
(adjusted P¼0.0486, OR 0.616; 95% CI: 0.381–0.997).
There was no significant SVR difference between the
patients with INTRON plus ribavirin (76.6%) and those
with pegylated IFN-a plus ribavirin (77.8%) albeit the
percentage of patients with high viral RNA were lower
in INTRON plus ribavirin group (19.0%) than that in
pegylated IFN-a plus ribavirin (48.8%) group. Viral
genotypes were significantly associated with SVR.
Patients with non-HCV genotype 1 infection (91.4%;
278 of 304) were more likely to reveal SVR than the
patients with HCV genotype 1 infection (66.3%) (ad-
justed P¼3.6 10
 12, OR 0.178; 95% CI: 0.110–0.290).
In addition, 86.6% of the patients with viral load
o400000IUml
–1 demonstrated SVR as compared with
64.2% of the patients with HCV viral load over
400000IUml
–1 (adjusted P¼2.3 10
 9, OR 0.292; 95%
CI: 0.195–0.437). Therefore, viral load appeared to
contribute significantly to the SVR in the therapy.
IL28B polymorphisms are associated with chronic HCV
infection
Ten SNPs of IL28B genetic variations were genotyped in
728 chronic HCV infection patients and 960 healthy
Table 1 Clinical characteristics and SVR analysis of Taiwanese patients with chronic HCV infection
Clinical characteristic Total (N¼728) SVR positive (N¼559) SVR negative (N¼169) P-value
Age on IFN therapy 51.2±10.4 50.1±10.5 54.8±9.3 o0.001*
Male 444 (61.0%) 361 (64.6%) 83 (49.1%) o0.001*
Liver cirrhosis 246 (33.8%) 155 (27.7%) 91 (53.8%) o0.001*
HCV genotype:
Genotype 1 424 (58.2%) 281 (50.3%) 143 (84.6%) o0.001*
Non-genotype 1 304 (41.8%) 278 (49.7%) 26 (15.4%)
HCV RNA Z0.4miu 318 (43.7%) 204 (36.5%) 114 (67.5%) o0.001*
BMI Z27kgm
–2 146 (20.1%) 106 (19.0%) 40 (23.7%) 0.181
Adherence 483 (66.3%) 386 (69.1%) 39 (23.1%) 0.005*
Regimen
INTRON+RBV 126 (17.3%) 98 (17.5%) 28 (16.6%) 0.772
PEG-IFN+RBV 602 (82.7%) 461 (82.5%) 141 (83.4%)
Abbreviations: BMI, body mass index; HCV, hepatitis C virus; PEG IFN, pegylated interferon; RBV, ribavirin; SVR, sustained virological
response.
*Po0.05.
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Genes and Immunitycontrols. As shown in Table 3, genotype distributions
and allele frequencies of two IL28B SNPs were signifi-
cantly different between patients with chronic HCV
infection and the normal healthy donors. The C allele of
SNP rs28416813 appeared to be a risk allele for HCV
infection (Trend test P¼1.0 10
 6 with 100000 permuta-
tions; G vs C adjusted P¼6.4 10
 7, OR 0.026, 95% CI:
0.006–0.110; genotypes CGþGG vs CC adjusted
P¼1.5 10
 5, OR 0.012, 95% CI: 0.002–0.089). In addi-
tion, the SNP rs8099917 genotypes appear to be a
predisposition factor for HCV infection (genotype GG
vs GTþTT adjusted P¼0.001, OR 0.034; 95% CI: 0.004–
0.254). Therefore, the SNP rs8099917 GG could be
defined as the protective genotype. Notably, the SNP
rs8099917 GG genotype frequency of the normal control
males tested negative for HCV antibody was 21.5 times
of that in the male patients with HCV infection (Table 4).
Significant deviations from Hardy–Weinberg equili-
brium in genotype and allele distributions were ob-
served for SNP rs28416813 and rs8099917 in both HCV
patients and normal controls (Po0.05).
IL28B polymorphisms are associated with SVR in the
treatment of chronic HCV infection
Patients with chronic HCV infection may manifest
heterogeneous clinical characteristics and exhibit differ-
ent SVRs to IFN therapy. Hence, we stratified patients
into two groups in accordance with SVR to the treatment.
As shown in Table 3, genotype distributions of the eight
SNPs (rs12980275, rs8105790, rs11881222, rs4803219,
rs12979860, rs8099917, rs7248668 and rs10853728) were
significantly different between SVR positive and nega-
tive patients (Trend test P¼0.005 with 100000 permuta-
tions). The advantageous alleles of IL28 polymorphisms
had similarly high frequencies in SVR positive groups
(Table 5). Consequently, we examined whether IL28B
SNP haplotypes were associated with SVR based on
linkage disequilibrium blocks (Figure 1). As shown in
Table 6, IL28B haplotypes ACC (rs11881222, rs4803219
and rs12979860), AT (rs12980275 and rs8105790),
ATA (rs12980275, rs8105790 and rs11881222) and TA
(rs8105790 and rs11881222) revealed as low responder
alleles. Our data suggest that genetics of IL28B may
impact the SVR in the treatment of HCV infection in
Taiwanese.
IL28B polymorphisms are associated with HCV genotypes
of chronic HCV infection
We also investigated possible interactions of IL28B
polymorphisms with other clinical characteristics of
chronic HCV infection in Taiwanese. We observed
significant association (Po0.05) between HCV genotypes
and IL28B SNP rs8099917 (Trend test P¼0.03 with
100000 permutations; G vs T adjusted P¼0.0318, OR
1.729, 95% CI: 1.049–2.851) and between HCV genotypes
and rs7248668 (Trend test P¼0.028 with 100000 permu-
tations; A vs G adjusted P¼0.0267, OR 1.777, 95% CI:
1.069–2.956). Our data suggest that IL28B gene products
may associate with certain strains of HCV infection.
Next, we performed multivariate analysis to compara-
tively evaluate the independent contribution of the
significant IL-28B SNPs and the non-genetic clinical
characteristics. Notably, rs12979860 is the only IL28B
SNP showed significant association in multivariate
analysis (P¼2.3 10
 8, OR 0.177, 95% CI: 0.096–0.324).
Discussion
Chronic HCV infection involves in a complex interaction
of virus with host innate and adaptive immunity.
Table 2 Clinical characteristics significantly affect SVR by multiple varieties analysis in 728 Taiwanese chronic HCV infection patients
Clinical characteristics N Stepwise logistic regression
OR 95% CI P-value
Age on IFN therapy 728 0.962 0.942–0.983 0.0004
Gender: female 284 1.705 1.140–2.549 0.0093
BMI: below 27kgm
–2 582 0.616 0.381–0.997 0.0486
HCV RNA viral load r 400000IUml
–1 410 0.292 0.195–0.437 2.3 10
 9
HCV genotype: Non-genotype 1 304 0.178 0.110–0.290 3.6 10
 12
Liver biopsy: non-cirrhosis 482 0.379 0.251–0.573 4.1 10
 6
Abbreviations: BMI, body mass index; CI, confidence interval; HCV, hepatitis C virus; OR, odds ratio; SVR, sustained virological response.
Table 3 Allele and genotype distributions of IL28B SNPs in 728 Taiwanese chronic HCV infection patients and 960 normal controls
SNP marker Risk allele RAF (normal) RAF (HCV) Ptrend Genotypes/alleles Age, sex adjusted
P-value OR (95% CI)
rs28416813 C 0.975 0.999 1.0 10
 6 C/G+G/G vs C/C 1.5 10
 5 0.012 (0.002–0.089)
G vs C 6.4 10
 7 0.026 (0.006–0.110)
rs8099917 T 0.936 0.947 0.2006 G/G vs G/T+T/T 0.0010 0.034 (0.004–0.254)
G vs T 0.0425 0.713 (0.515–0.989)
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; OR, odds ratio; RAF (normal) and RAF (HCV), risk allele frequency in normal
controls and HCV patients; SNP, single-nucleotide polymorphism.
Ptrend value were calculated by the Cochran–Armitage trend test with permutation¼100000.
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Genes and ImmunityAlthough the acute infections are highly amenable to
therapy, approximately 80% HCV infections progress to
viral persistence.
2,5 Several host factors including alcohol
intake, age at the time of infection, gender and co-
infection with the hepatitis B virus or human immuno-
deficiency virus are known to affect disease courses in
HCV infection.
1,5,13,14 Accumulating evidence supports a
critical role of host genetics in immune responses, which
may predict the treatment response and outcome of viral
clearance.
18,30,31 Consistent with previous reports, this
study established a predictive role of IL28B polymorph-
isms in the treatment of chronic HCV infection with
IFN-a plus ribavirin in Taiwanese patients.
HCV evades the host immune surveillance by trigger-
ing production of viral inhibitory enzymes and negative
signal regulatory proteins that block signal transduction
pathways of human innate immune system.
19,32 In
addition, HCV employs multiple escaping strategies
including viral genetic variability (genotype switches),
baseline viral load, quasi-species entity and high viral
turnover to protect HCV from host humoral and cellular
immunity.
16,19,32,33 Our data provided direct evidence that
HCV genotype 1 and high basal viral load are two key
factors for SVR in the treatment of Taiwanese HCV
patients.
IFN-l1 (IL29), IFN-l2 (IL28A) and IFN-l3 (IL28B)
belong to type II cytokine family induced by virus
infections. Besides their antivirus activities, IFN-ls are
capable of modulating innate immune response effects.
21
IFN-ls bind to the heterodimeric receptors of specific
IFN-lR1 and common IL10R2, which form a trimeric ISG
factor complex that triggers a cascade of signal transduc-
tions.
34 The binding of ISG factor to IFN response
elements results in steady upregulations of several ISGs
with antiviral effects.
35–38 In animal models, the antiviral
activity of Toll-like receptor signaling pathways induced
by Toll-like receptor-3 and 9 agonists was significantly
decreased in IL28R1 knockout mice.
39 In gene expression
comparison studies, peripheral blood and liver tissue
cells in chronic HCV infection with low SVR in response
to IFN/ribavirin therapy display a defect in ISG
production, which may be due to pre-activated states
in blunted IFN cell signaling.
40–42 These findings point to
the critical roles of host genetic variations in IFN-a-
mediated innate immune signal pathways that may
affect chronic HCV infection course and treatment
response. Indeed, certain host genetic polymorphisms
involving in IFN signal pathways and ISGs have shown
modest effects on IFN-a treatment response in patients
infected with HCV.
43–45
HCV persistent infection induces a cascade of innate
and adaptive immune cellular dysfunctional changes.
4,17
IFN-ls produced by monocyte-derived dendritic cells
and plasmacytoid dendritic cells facilitate viral clearance
by influencing innate and adaptive immunities.
22,46,47
IL29 and IFN-a modulate the co-stimulatory molecules
expressions on plasmacytoid dendritic cells and lead to
signature cytokines production.
48 In addition, IL29
modulates the Th1/Th2 differentiation that favors the
pro-inflammatory (Th1) response, which enhance adap-
tive cellular immunity to eradicate virus infection.
49–52
During vaccination, IL28B increases the cytolytic CD8T
cell differentiations and suppresses the of T regulatory
cell productions, which protect animals from mortality
after a lethal influenza challenge.
52 These immunological
T
a
b
l
e
4
C
o
n
t
i
n
u
e
d
C
l
i
n
i
c
a
l
S
V
R
p
o
s
i
t
i
v
e
S
V
R
n
e
g
a
t
i
v
e
H
C
V
N
o
r
m
a
l
c
h
a
r
a
c
t
e
r
i
s
t
i
c
/
I
L
2
8
B
S
N
P
s
M
a
l
e
(
N
¼
3
6
0
)
F
e
m
a
l
e
(
N
¼
1
9
9
)
T
o
t
a
l
(
N
¼
5
5
9
)
M
a
l
e
(
N
¼
8
3
)
F
e
m
a
l
e
(
N
¼
8
6
)
T
o
t
a
l
(
N
¼
1
6
9
)
M
a
l
e
(
N
¼
4
4
3
)
F
e
m
a
l
e
(
N
¼
2
8
5
)
T
o
t
a
l
(
N
¼
7
2
8
)
M
a
l
e
(
N
)
a
F
e
m
a
l
e
T
o
t
a
l
r
s
1
0
8
5
3
7
2
8
C
C
0
.
6
5
3
0
.
7
1
4
0
.
6
7
4
0
.
5
5
4
0
.
5
4
7
0
.
5
5
0
0
.
6
3
4
0
.
6
6
3
0
.
6
4
6
0
.
6
7
8
0
.
6
7
6
0
.
6
7
8
C
G
0
.
3
1
9
0
.
2
6
1
0
.
2
9
9
0
.
3
4
9
0
.
4
3
0
0
.
3
9
1
0
.
3
2
5
0
.
3
1
2
0
.
3
2
0
0
.
2
8
1
0
.
2
9
4
0
.
2
8
7
G
G
0
.
0
2
8
0
.
0
2
5
0
.
0
2
7
0
.
0
9
6
0
.
0
2
3
0
.
0
5
9
0
.
0
4
1
0
.
0
2
5
0
.
0
3
4
0
.
0
4
1
0
.
0
2
9
0
.
0
3
6
A
b
b
r
e
v
i
a
t
i
o
n
s
:
H
C
V
,
h
e
p
a
t
i
t
i
s
C
v
i
r
u
s
;
S
N
P
,
s
i
n
g
l
e
-
n
u
c
l
e
o
t
i
d
e
p
o
l
y
m
o
r
p
h
i
s
m
;
S
V
R
,
s
u
s
t
a
i
n
e
d
v
i
r
o
l
o
g
i
c
a
l
r
e
s
p
o
n
s
e
.
a
N
o
r
m
a
l
m
a
l
e
(
N
¼
5
1
4
,
5
1
4
,
5
1
4
,
5
1
4
,
5
1
4
,
5
1
4
,
5
1
4
,
5
1
3
,
5
1
4
,
5
1
3
,
5
1
3
)
;
n
o
r
m
a
l
f
e
m
a
l
e
(
N
¼
4
4
5
,
4
4
6
,
4
4
4
,
4
4
6
,
4
4
6
,
4
4
6
,
4
4
6
,
4
4
6
,
4
2
2
,
4
4
5
)
;
n
o
r
m
a
l
t
o
t
a
l
(
N
¼
9
5
9
,
9
6
0
,
9
5
8
,
9
6
0
,
9
6
0
,
9
6
0
,
9
5
9
,
9
6
0
,
9
3
5
,
9
5
8
)
.
IL28B-associated SVR in Taiwanese chronic HCV infection
J-Y Chen et al
304
Genes and Immunityresponses collectively suggest IFN-ls are critical
in suppressing viral replication during HCV chronic
infection. However, the mechanisms that IL28B SNPs are
associated with the response to IFN-a-based therapy
remain to be elucidated in humans.
In therapy with pegylated IFN-a plus ribavirin, the
adverse events and failure of response sometimes
occurred.
13 The novel HCV treatment strategies are still
under development to improve sustained response rates.
IFN-ls have several important roles in controlling
chronic HCV infections and may be useful in future
therapy. IFN-ls can enhance the subsaturating levels of
IFN-a and increase the antiviral efficacy.
35 The combina-
tion of IFN-ls and IFN-as may provide the additive
therapy effect through the complementary roles of two
types of cytokines.
37,38,53 As the distribution of IFN-l
receptors are restricted on plasmacytoid dendritic cells,
peripheral B cell, hepatocytes and epithelial cells, IFN-ls
may be used to target specific cell responses and to avoid
the adverse events of therapy of IFN-as.
53,54
Genome-wide association studies in independent
populations confirmed that IL28B genetic variations are
associated with HCV IFN-based therapy response and
spontaneous clearance of HCV.
25–29 In this study, we
compared genotypes and alleles frequency of IL28B
SNPs between normal controls and patients with chronic
HCV infection in Taiwanese. In Caucasians and Africans,
IL28B SNP rs12979860 CC genotype and C allele are
associated with spontaneous resolution of HCVinfection,
however, no differences in genotype and allele distribu-
tions were observed for IL28B SNP rs12979860 between
HCV patients and normal controls in Taiwanese. Para-
doxically, rs8099917 GG genotype and rs28416813 G
allele that associated with low response in Australians
and Japanese were significantly enriched in Taiwanese
normal male population. On the other hand, eight SNPs
with strong linkage disequilibrium demonstrate signifi-
cant associations with SVR on single point analysis.
However, haplotype analysis failed to increase the
significance of association, which is different from the
results of previous studies.
26,27 These findings suggest
that various IL28B SNPs are associated with the treat-
ment response of HCV in Taiwanese. Nevertheless, the
exact causal roles of IL28B polymorphisms remain to be
elucidated.
The combinational treatment of pegylated IFN-a and
ribavirin is widely applied to chronic HCV infection.
The treatment results in sustained clearance of virus
and clinical improvement in various ethnic popula-
tions.
13,55–58 However, the response rates showed ethnic
difference with poor response in patients of African
Table 5 Association of IL28B SNPs with SVR in Taiwanese patients with chronic HCV infection
SNP
marker
Risk
allele
RAF
(NR)
RAF
(SVR)
Ptrend Genotypes/alleles Age, sex adjusted Stepwise logistic regression
P-value OR (95% CI) P-value OR (95% CI)
rs4803219 C 0.899 0.966 2.0 10
 6 C/T vs C/C 3.7 10
 7 0.258 (0.153–0.435) 1.4 10
 7 0.191 (0.103–0.354)
T vs C 7.4 10
 7 0.284 (0.172–0.467) 2.1 10
 7 0.213 (0.119–0.382)
rs12979860 C 0.891 0.966 1.0 10
 6 C/T+T/T vs C/C 4.4 10
 8 0.236 (0.140–0.395) 3.1 10
 8 0.181 (0.099–0.331)
T vs C 3.5 10
 8 0.252 (0.155–0.411) 2.9 10
 8 0.200 (0.113–0.353)
rs11881222 A 0.894 0.964 1.0 10
 6 A/G+G/G vs A/A 2.1 10
 7 0.256 (0.153–0.428) 1.1 10
 7 0.195 (0.107–0.356)
G vs A 1.6 10
 7 0.272 (0.167–0.443) 9.0 10
 8 0.214 (0.121–0.376)
rs12980275 A 0.899 0.959 4.9 10
 5 A/G+G/G vs A/A 3.4 10
 6 0.302 (0.182–0.500) 2.0 10
 6 0.241 (0.134–0.433)
G vs A 1.0 10
 5 0.340 (0.211–0.549) 4.3 10
 6 0.275 (0.158–0.476)
rs8105790 T 0.896 0.962 9.0 10
 6 C/C+C/T vs T/T 1.3 10
 6 0.282 (0.169–0.471) 5.5 10
 7 0.222 (0.123–0.400)
C vs T 9.5 10
 7 0.298 (0.184–0.484) 7.5 10
 7 0.248 (0.143–0.431)
rs8099917 T 0.896 0.962 5.0 10
 6 G/G+G/T vs T/T 9.6 10
 7 0.277 (0.165–0.462) 4.3 10
 7 0.217 (0.120–0.392)
G vs T 7.1 10
 7 0.293 (0.180–0.476) 6.2 10
 7 0.245 (0.141–0.426)
rs7248668 G 0.896 0.964 4.0 10
 6 A/A+A/G vs G/G 6.1 10
 7 0.268 (0.160–0.450) 3.6 10
 6 0.246 (0.136–0.445)
A vs G 4.5 10
 7 0.283 (0.173–0.462) 4.5 10
 6 0.270 (0.154–0.472)
rs10853728 C 0.746 0.924 0.0015 G/G+C/G vs C/C 0.0007 0.533 (0.371–0.767) 0.0006 0.485 (0.322–0.731)
G/G vs C/G+C/C 0.0109 0.330 (0.141–0.775) 0.0117 0.291 (0.111–0.759)
G vs C 0.0002 0.564 (0.418–0.761) 0.0002 0.527 (0.375–0.740)
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; NR, no response; OR, odds ratio; RAF, risk allele frequency; SNP, single-
nucleotide polymorphism; SVR, sustained virological response.
Risk allele, the allele with higher frequency in cases compared with controls.
Ptrend value was calculated by the Cochran–Armitage trend test with 100000 permutations.
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Figure 1 Pairwise linkage disequilibrium (LD) patterns for eight
polymorphisms through IL28B regions.
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Genes and Immunityancestry and Hispanic ancestry in comparison with
patients of Caucasian ancestry.
55,56 We observed higher
SVR rates in Taiwanese chronic HCV infection who
received IFN-a and ribavirin combination therapy,
similar to the previous findings in Asians.
57,58 The
IL28B genetic variations affect mRNA expressions,
indicating functional polymorphisms in regulatory re-
gions may interfere with treatment responses.
26,27 This
study confirmed that IL28B SNPs are associated with
SVR of HCV treatment response across all ethnic groups.
The advantageous IL28B SNPs have significantly higher
frequencies in Asian populations than in populations
with African and Caucasian ancestry origins, which may
provide explanation for the ethnic differences in SVR
in IFN-based therapy among Asians, Europeans and
Africans.
Recognizing the cost-effective concern and the poten-
tially serious adverse effects, investigators and clinicians
put emphasis on the importance of predicting the
response to IFN-based biologic therapy. The longer
duration of treatment achieved significantly higher SVR
rates than the shorter course therapy, which may indicate
the specific refractory cases with genotype 1 infec-
tion.
58,59 Human genome variations explain part of the
different effective responses. The combination of data
including virus genotypes, viral load, immunological
cellular and gene expression changes, and host genetic
variations may be critical to determine individual
appropriate treatment doses and duration, which is
valuable to minimize the adverse effects of biologic
agents. This study could provide another critical evi-
dence for usefulness of application of genetic data in
clinical settings for predicting the treatment response. In
Asians, patients carrying IL28B low response alleles and
genotypes could be identified for longer antiviral
treatment. However, SVR of HCVinfection is determined
by multiple genetic loci. The practical utility of genetic
data in treatment choice remains to be determined for
IFN-based therapy.
In conclusion, IFN-ls appear as critical functional
immune response molecules that could be therapeutic
target in the treatment of persistent HCV infections.
Genetic data of IL28B SNPs may provide novel guide-
lines in determining optimal treatment duration with
IFN-based therapies.
Materials and methods
Study subjects
This study recruited 728 patients from the Hepatology
clinics of Linkou Medical Center, Chang Gung Memorial
Hospital. Hepatology specialists confirmed the chronic
HCV infection clinically and verified the diagnosis with
liver biopsies in all examined patients. Two cohorts of
patients with chronic hepatitis C were analyzed. Patients
in cohort A were treated with INTRON plus ribavirin
(126 patients, January 1988 to October 2001) and patients
in cohort B were treated with pegylated IFN plus
ribavirin (604 patients, November 2001 to December
2008). All patients were positive for anti-HCV (for 46
months) and for HCV–RNA. In addition, HCV from each
patient was genotyped and the infections were verified
with pathological findings before the enrolment for
treatment. The patients in cohort A received INTRON
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Genes and Immunity(IFN-a 2b, Schering Co., Kenilworth, NJ, USA) 5 MU
three times a week and ribavirin 1200mg per day. The
cohort B patients received ribavirin 1200mg per day
and PEGINTRON (15mgkg
–1week
–1, Peginterferon-a 2b,
Schering Co.) or PEGASYS (180mgweek
–1, Peginterferon-
a 2a, Roche). For the purpose of this study, a total of 960
healthy blood donors (514 men and 446 women) were
recruited following a questionnaire survey to exclude
any donors with autoimmune diseases including rheu-
matoid arthritis, systemic lupus erythematous, ankylos-
ing spondylitis, and autoimmune thyroiditis, diabetes
mellitus, viral hepatitis (HBV and HCV) infections and
cardiovascular diseases. The age of healthy control
donors ranges from 18 to 64 years old with a mean age
of 40.3±10.7.
HCV infection assays
Clinical characteristics including liver biochemical test,
HCV genotypes, HCV viral load, liver histology and
therapeutic responses to the combination regimen (IFN-a
plus ribavirin). The HCV antibody was tested by the
Abbott AxSYM anti-HCV 3.0 (Abbott Laboratories,
Abbott Park, IL, USA). The HCV RNA detection was
carried out with Cobas Amplicor HCV v2.0 kit (Roche
Diagnostics Co., Indianapolis, IN, USA; lower limit of
detection of at concentrations of 50IUml
–1) and RNA
was quantitated by the VERSANT HCV RNA 3.0 Assay
(bDNA) (Bayer Diagnostics, Berkeley, CA, USA; lower
limit of detection of at 615IUml
–1) or COBAS TaqMan
HCV Test (TaqMan HCV; Roche Molecular Systems Inc.,
Branchburg, NJ, USA; lower limit of detection of at
concentrations of 15IUml
–1). The baseline levels of
HCV–RNA were determined by VERSANT HCV RNA
3.0 Assay in 669 patients and confirmed by Cobas
Amplicor HCV v2.0 before January, 2008. Thereafter,
COBAS TaqMan HCV Test was applied in 59 patients.
HCV RNA level o2 MEQ (equal to 400000IUml
–1) was
defined as low viral load. HCV genotypes were analyzed
using a genotype-specific probe-based assay in the 50
untranslated region.
Clinical SVR and liver biopsy
SVR was defined when serum HCV–RNA was undetect-
able at the end of therapy and at 24-week follow-up after
the treatment. Non-response was designated when viral
RNA reappears within 6 months after the cessation of
treatment; or when viral load decreases o2 logs after 12-
week treatment, or when viral RNAwas detectable at the
end of treatment. The liver biopsy was interpreted and
graded by Ishak classification. In the analysis, we
categorized fibrosis into cirrhosis (fibrosis score 5 or 6),
severe fibrosis (fibrosis score 4) and mild fibrosis (fibrosis
score 1 or 2 or 3).
Nucleic acid isolation
Anti-coagulated peripheral blood was obtained from
healthy normal blood donors and HCV patients. Geno-
mic DNA was isolated from EDTA anti-coagulated
peripheral blood using the Puregene DNA isolation kit
(Gentra Systems, Minneapolis, MN, USA) as previously
described.
60
Taqman-based assay for the genotyping of SNPs
The oligonucleotide sequences flanking IL28B poly-
morphisms were designed as primers for Taqman allelic
discrimination assays. Allele-specific primers were la-
beled with a fluorescent dye (FAM or VIC) and used in
the PCR reaction. Aliquots of the PCR products were
genotyping using allele specific probe of SNPs on a real-
time PCR Thermocylcler (ABI, Foster City, CA, USA).
Statistical analysis
We carried out single-locus analyses of IL28B poly-
morphisms for 960 normal healthy controls and 728
patients with chronic HCV infection. Three w
2 tests: the
genotype test, the allele test and Cochran–Armitage
trend test were performed, and associations with SNPs
(Po0.05) were identified using the SAS/Genetics soft-
ware package release 8.2 (SAS Institute, Cary, NC, USA).
For the analysis of risk genotypes/alleles, we used
logistic regression models adjusted for age and sex and
calculated P-values, ORs, and their 95% CIs. Linkage
disequilibrium between marker loci was assessed and
haplotype blocks were constructed using Haploview 4.1
(Broad Institute of MIT and Harvard; http://www.
broad.mit.edu/mpg/haploview). For the markers within
the same haplotype block, we used disease status (case
vs control) and five clinical characteristics: body mass
index, drug, HCV genotype, HCV RNA viral load and
SVR as traits and tested for the haplotype–trait associa-
tion utilizing SAS HAPLOTYPE procedure. To investi-
gate the genetic association with clinical characteristics
including body mass index, drug, HCV genotype, HCV
RNA viral load and SVR for the case group, we
controlled for each of these five characteristics and
performed stepwise logistic regression analyses. Addi-
tionally, we examined the association of SVR with age on
IFN therapy, gender, body mass index, HCV RNA viral
load, HCV genotype, adherence and degrees of liver
fibrosis in the chronic HCV infection patients using
Student’s t-test and w
2 test. The 5% level of significance
for P-values was used for all the analyses.
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